Quick Answer
Atea Pharmaceuticals, Inc. reported Stockholders Equity of $275.43 million for the year ending 2025.
- Atea Pharmaceuticals, Inc. showed a decrease of -37.2% in Stockholders Equity from 2024 to 2025.
- This data is from Atea Pharmaceuticals, Inc.'s annual report (Form 10-K), filed with the SEC on March 5, 2026.
- XBRL data for this metric is available from 2017 to 2025 (9 years of filings). Earlier data may not exist in machine-readable XBRL format as companies adopted electronic filing at different times.
- Quarterly values from 10-Q filings: Q1 2019: -$38.21 million | Q2 2019: -$41.62 million | Q3 2019: -$45.09 million | Q1 2020: -$53.37 million | Q2 2020: -$63.13 million | Q3 2020: -$76.51 million | Q1 2021: $586.26 million | Q2 2021: $597.86 million | Q3 2021: $581.45 million | Q1 2022: $679.88 million | Q2 2022: $660.46 million | Q3 2022: $663.19 million | Q1 2023: $618.18 million | Q2 2023: $602.35 million | Q3 2023: $581.73 million | Q1 2024: $504.37 million | Q2 2024: $476.47 million | Q3 2024: $458.52 million | Q1 2025: $411.08 million | Q2 2025: $364.42 million | Q3 2025: $315.78 million.
- Over the full 9 years of available data (2017 to 2025), Atea Pharmaceuticals, Inc.'s Stockholders Equity has grown by 1,101.2%.
- Historical annual values: Fiscal year 2025: $275.43 million | Fiscal year 2024: $438.87 million | Fiscal year 2023: $555.19 million | Fiscal year 2022: $640.57 million | Fiscal year 2021: $710.08 million | Fiscal year 2020: $547.80 million | Fiscal year 2019: -$49.57 million | Fiscal year 2018: -$36.16 million | Fiscal year 2017: -$27.51 million.
- Data sourced from SEC EDGAR public filings as of August 4, 2026.
Last verified: